In the past week, CAPR stock has gone down by -18.94%, with a monthly decline of -25.63% and a quarterly surge of 22.28%. The volatility ratio for the week is 10.83%, and the volatility levels for the last 30 days are 8.35% for Capricor Therapeutics Inc The simple moving average for the last 20 days is -22.38% for CAPR stock, with a simple moving average of 7.73% for the last 200 days.
Is It Worth Investing in Capricor Therapeutics Inc (NASDAQ: CAPR) Right Now?
CAPR has 36-month beta value of 4.06. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CAPR is 28.79M, and currently, short sellers hold a 12.16% ratio of that float. The average trading volume of CAPR on April 19, 2024 was 270.00K shares.
CAPR) stock’s latest price update
Capricor Therapeutics Inc (NASDAQ: CAPR) has seen a decline in its stock price by -9.01 in relation to its previous close of 5.55. However, the company has experienced a -18.94% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-10 that The average of price targets set by Wall Street analysts indicates a potential upside of 218.2% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Analysts’ Opinion of CAPR
Many brokerage firms have already submitted their reports for CAPR stocks, with Cantor Fitzgerald repeating the rating for CAPR by listing it as a “Overweight.” The predicted price for CAPR in the upcoming period, according to Cantor Fitzgerald is $8 based on the research report published on January 05, 2024 of the current year 2024.
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see CAPR reach a price target of $15. The rating they have provided for CAPR stocks is “Buy” according to the report published on October 26th, 2022.
CAPR Trading at -6.95% from the 50-Day Moving Average
After a stumble in the market that brought CAPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.57% of loss for the given period.
Volatility was left at 8.35%, however, over the last 30 days, the volatility rate increased by 10.83%, as shares sank -26.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.57% upper at present.
During the last 5 trading sessions, CAPR fell by -18.94%, which changed the moving average for the period of 200-days by +7.45% in comparison to the 20-day moving average, which settled at $6.42. In addition, Capricor Therapeutics Inc saw 3.27% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CAPR starting from Musket David B, who purchase 410 shares at the price of $2.75 back on Oct 12 ’23. After this action, Musket David B now owns 31,536 shares of Capricor Therapeutics Inc, valued at $1,128 using the latest closing price.
COLLIER EARL M JR, the Director of Capricor Therapeutics Inc, purchase 10,000 shares at $2.83 during a trade that took place back on Oct 10 ’23, which means that COLLIER EARL M JR is holding 26,856 shares at $28,300 based on the most recent closing price.
Stock Fundamentals for CAPR
Current profitability levels for the company are sitting at:
- -0.95 for the present operating margin
- 0.66 for the gross margin
The net margin for Capricor Therapeutics Inc stands at 15.65. The total capital return value is set at -0.87. Equity return is now at value -129.63, with -40.96 for asset returns.
Based on Capricor Therapeutics Inc (CAPR), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -6.2. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -0.06.
Currently, EBITDA for the company is -23.01 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 5.96. The receivables turnover for the company is 2.43for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.63.
Conclusion
To put it simply, Capricor Therapeutics Inc (CAPR) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
